*Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia †Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA ‡Division of Hematopathology, Mayo Clinic, Rochester, MN.
Adv Anat Pathol. 2014 Jan;21(1):12-25. doi: 10.1097/PAP.0000000000000002.
Hodgkin lymphoma (HL) encompasses 2 unique clinicopathologic entities, classical Hodgkin lymphoma (CHL) (∼95% of cases) and nodular lymphocyte predominant HL (∼5% of cases). Both subtypes demonstrate a paucity of surreptitious (in CHL) neoplastic B cells within a background of reactive inflammatory cells underscoring both the relatedness of these 2 entities to each other, as well as their distinction from other types of lymphoid neoplasia. Clinically, they are primarily nodal diseases that disseminate in a predictable manner to contiguous nodal regions. The biology of HL as a whole, as well as the genetic and pathologic features that distinguish CHL from nodular lymphocyte predominant HL and other lymphomas has been the subject of a wealth of investigation in recent decades. The aim of this review is to detail the pathologic features of HL and to highlight the recent insights into its molecular basis and the myriad prognostic markers being described.
霍奇金淋巴瘤（HL）包括 2 种独特的临床病理实体，经典霍奇金淋巴瘤（CHL）（∼95%的病例）和结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）（∼5%的病例）。这两种亚型都表现为在反应性炎症细胞背景下，隐匿性（在 CHL 中）肿瘤性 B 细胞数量减少，这突出了这两种实体之间的相关性，以及它们与其他类型的淋巴肿瘤的区别。临床上，它们主要是淋巴结疾病，以可预测的方式扩散到相邻的淋巴结区域。HL 的生物学，以及区分 CHL 与 NLPHL 和其他淋巴瘤的遗传和病理特征，是近几十年来大量研究的主题。本综述的目的是详细描述 HL 的病理特征，并强调其分子基础的最新见解以及正在描述的众多预后标志物。
